Delcath Systems receives $16.3M from Series E and E1 warrant exercises

DELCATH SYSTEMS, INC.

1,746,424 warrants exercised; 1,045,157 shares of common stock and 603,954 pre-funded warrants issued.
Gross proceeds of approximately $16.3 million; ~6.6% of exercises were cashless.
Warrants had $10.00 exercise price, issued in July/August 2019, expired Dec 24, 2024.
CEO states cash position strong to fund HEPZATO commercialization and clinical trials.
Warrant amendments allow pre-funded warrants to avoid exceeding 9.99% beneficial ownership cap.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.